7 unchanged sentences
001-40925), filed with the Securities and Exchange Commission on April 3, 2023)
−Removed: Third Amended and Restated Employment Agreement, dated August 3, 2024, by and between the Registrant and Christopher Frankenfield (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No.
−Removed: 001-40925), filed with the Securities and Exchange Commission on August 8, 2024)
+Added: Collaboration, License and Option Agreement, dated February 10, 2025, between Xilio Development, Inc.
+Added: and AbbVie Group Holdings Limited
+Added: Common Stock Purchase Agreement, dated February 10, 2025, between the Registrant and AbbVie Inc.
+Added: Investor Rights Agreement, dated February 10, 2025, between the Registrant and AbbVie Inc.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
Filed herewith.
−Removed: Indicates management contract or compensatory plan or arrangement.
The certifications attached as Exhibit 32.1 are being furnished solely to accompany this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section.
Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference into such filing.
+Added: Portions of this exhibit have been omitted pursuant to Item 601 of Regulation S-K promulgated under the Securities Act because the information is not material and is a type of information that the Registrant treats as private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
XILIO THERAPEUTICS, INC.
−Removed: November 7, 2024
/s/ René Russo
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 7, 2024
/s/ Christopher Frankenfield
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.